Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Single Dose of Ambisome for Visceral Leishmaniasis
NCT00832208Phase 2Terminated
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Apr 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of amphotericin b in visceral leishmaniasis (VL), sponsored by Drugs for Neglected Diseases initiative. Started Apr 2009; status: terminated.
02
Drugs
amphotericin b
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT00832208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00832208.